Drug intelligence / Profile preview

WO3979

Development stage: Unknown
Lead developer: Dr August Wolff
Modality: Small Molecules
Administration: Topical

Overview

WO3979 is an investigational topical formulation containing glycopyrronium bromide, developed by Dr. August Wolff GmbH & Co. KG Arzneimittel. It is being evaluated for the treatment of axillary hyperhidrosis, a condition characterized by excessive underarm sweating. Glycopyrronium bromide acts as an anticholinergic agent, blocking muscarinic receptors to reduce sweat production.

Other names: GPB topical formulation

Targets

mAChR (Muscarinic acetylcholine receptors)

Beyond the preview

Go deeper on WO3979.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WO3979.

Explore the full profile